STAT+: The China debate gets louder in Washington

STAT+ highlighted a growing debate in Washington regarding China's increasing influence in the biopharmaceutical sector. The publication noted that Eli Lilly is pursuing aesthetic applications with an AI-designed experimental hair loss drug developed by Absci. Concurrently, the United States is experiencing a significant increase in healthcare spending. The article also points to China's expanding role within the biopharma industry, suggesting this trend is a key focus of discussions in Washington.